CRA International director Tookes sells $14,599 in company stock By Investing.com

Heather Tookes, a director at CRA International, Inc. (), disposed of 88 shares of the company’s common stock on July 23, 2026. The shares were sold at a price of $165.9 per share, totaling $14,599. The stock currently trades at $173.66, up from the sale price, with the company maintaining a market capitalization of $1.1 billion.

The transaction was executed under a Rule 10b5-1 trading plan, which Ms. Tookes adopted on March 14, 2025. Following this sale, Ms. Tookes beneficially owns 3,718 shares of CRA International common stock. Despite the insider sale, InvestingPro data reveals the company has raised its dividend for 10 consecutive years and currently offers a 1.31% yield. The stock trades at a P/E ratio of 24.05, and according to InvestingPro’s Fair Value analysis, appears overvalued at current levels. For investors seeking deeper insights, CRAI is among the 1,400+ US equities covered by comprehensive Pro Research Reports, available exclusively on InvestingPro.

In other recent news, Charles River Associates reported a record-breaking revenue of $201 million for the first quarter of 2026, marking a 10.5% increase compared to the previous year. However, the company’s earnings per share (EPS) were slightly below expectations, coming in at $1.99 against a forecast of $2.06. In addition, BriaCell Therapeutics Corp. has engaged Charles River Associates and Kaleio, Inc. to assist in the commercialization planning for its investigational therapy, Bria-IMT. Charles River Associates will focus on evaluating epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in the United States. Meanwhile, Kaleio, Inc. will provide support for brand strategies and commercial-readiness solutions. These developments highlight ongoing strategic initiatives and financial results for both companies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.